Your search for dabigatran returned 36 results

For patients with atrial fibrillation hospitalized with stroke or transient ischemic attack, use of novel oral anticoagulants (NOACs) has increased over time.

Pradaxa (dabigatran etexilate capsules) 150mg, an oral direct thrombin inhibitor, will be made available by Boehringer Ingelheim on November 3, 2010.

Compared with warfarin, apixaban was correlated with reduced risk of major bleeding and intracranial bleeding (adjusted hazard ratios, 0.66 and 0.4, respectively) and dabigatran was correlated with reduced risk of intracranial bleeding (adjusted hazard ratio, 0.45) among patients with atrial fibrillation.

Investigators found an incremental increase in risks from oral anticoagulants as kidney function decreased, highlighting the need for more research to better understand bleeding risk and net benefit of treatment in the CKD population.

Boehringer Ingelheim announced that the FDA has approved Pradaxa (dabigatran etexilate capsules), an oral direct thrombin inhibitor, to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AFib).

Although more research is needed, data suggest that the cardioprotective effect of direct oral anticoagulants may extend to patients with advanced CKD.

New recommendations have been developed for the optimum management of atrial fibrillation.

Most people with nonvalvular atrial fibrillation (NVAF) should be taking oral anticoagulants to prevent stroke.

For patients with atrial fibrillation, decline in renal function is significantly greater with warfarin vs. dabigatran etexilate (DE), according to a study published in the Journal of the American College of Cardiology.

For patients undergoing lower-extremity arthroplasty, a mobile compression device is noninferior to pharmacological protocols for the prevention of venous thromboembolism.